{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:01:36Z","timestamp":1792623696612,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1023\/a:1020669705369","type":"journal-article","created":{"date-parts":[[2003,3,18]],"date-time":"2003-03-18T15:27:35Z","timestamp":1048001255000},"page":"389-393","source":"Crossref","is-referenced-by-count":38,"title":["A Phase II Study of Thalidomide in Advanced Metastatic Renal Cell Carcinoma"],"prefix":"10.1007","volume":"20","author":[{"given":"David R.","family":"Minor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Monroe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa A.","family":"Damico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Suryadevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"5098311_CR1","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJM196212132672407","volume":"267","author":"GW Mellin","year":"1962","unstructured":"Mellin GW, Katzenstein M: The sage of thalidomide (concluded): neuropathy to embryopathy, with case reports of congenital anomalies. N Eng J Med 267:1238\u20131244, 1962","journal-title":"N Eng J Med"},{"issue":"5","key":"5098311_CR2","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1053\/ctrv.2000.0188","volume":"26","author":"SV Rajkumar","year":"2000","unstructured":"Rajkumar SV, Witzig TE: A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. Cancer Treat Rev 26(5):351\u2013362, 2000","journal-title":"Cancer Treat Rev"},{"key":"5098311_CR3","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","volume":"341","author":"S Singhal","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeddis J, Barlogie B: Antitumor activity of thalidomide in refractory multiple myeloma. N Eng J Med 341:1565\u20131571, 1999","journal-title":"N Eng J Med"},{"issue":"6","key":"5098311_CR4","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/S0002-9343(99)00408-8","volume":"108","author":"L Calabrese","year":"2000","unstructured":"Calabrese L, Fleischer AB: Thalidomide: current and potential clinical applications. Amer J Med 108(6):487\u2013495, 2000","journal-title":"Amer J Med"},{"key":"5098311_CR5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","volume":"18","author":"HA Fine","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK: Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Onc 18:708\u2013715, 2000","journal-title":"J Clin Onc"},{"key":"5098311_CR6","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1200\/JCO.2000.18.13.2593","volume":"18","author":"RF Little","year":"2000","unstructured":"Little RF, Wyvill KM, Pluda JM, Welles L, Marshall V, Figg WD, Newcomb FM, Tosato G, Feigel E, Steinberg SM, Whitby D, Goedert JJ, Yarchoan R: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 18:2593\u20132602, 2000","journal-title":"J Clin Oncol"},{"key":"5098311_CR7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","volume":"284","author":"CE Stebbins","year":"1999","unstructured":"Stebbins CE, Kaelin WG, Pavletich NP: Structure of the VHL-ElonginB complex: implications for VHL tumor suppressor function. Science 284:455\u2013461, 1999","journal-title":"Science"},{"key":"5098311_CR8","first-page":"1669","volume":"18","author":"JY Blay","year":"1999","unstructured":"Blay JY, Pallardy M, Ravaud A: Serum VEGF is an independent prognostic factor in patients (pts) with metastatic renal cell carcinoma treated with IL-2 and\/or IFN: analysis of the CRECY trial. Proc Amer Soc Clin Onc 18:1669, 1999","journal-title":"Proc Amer Soc Clin Onc"},{"key":"5098311_CR9","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","volume":"91","author":"RJ D'Amato","year":"1994","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA 91:4082\u20134085, 1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"5098311_CR10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0149-2918(00)88289-2","volume":"21","author":"JB Zeldis","year":"1999","unstructured":"Zeldis JB, Williams BA, Thomas SD, Elsayed ME, S.T.E.P.S.\u2122: a comprehensive program for controlling and monitoring access to thalidomide. Clin Ther 21:319\u2013330, 1999","journal-title":"Clin Ther"},{"key":"5098311_CR11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0022-1759(98)00131-8","volume":"219","author":"CR Rodriguez","year":"1998","unstructured":"Rodriguez CR, Fei DT, Keyt B, Baly DL: A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor165 in human plasma. J Immunological Methods 219:45\u201355, 1998","journal-title":"J Immunological Methods"},{"issue":"4","key":"5098311_CR12","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1054\/bjoc.1999.1004","volume":"82","author":"T Eisen","year":"2000","unstructured":"Eisen T, Boshoff C, Mak I: Continuous low dose Thalidonide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Brit J Cancer 82(4):812\u2013817, 2000","journal-title":"Brit J Cancer"},{"key":"5098311_CR13","first-page":"180a","volume":"20","author":"B Escudier","year":"2001","unstructured":"Escudier B, Lassau N, Couanet D, Angevin E, Leborgne S, Garofano A, Mesrati F, Laplanche A: A phase II trial of Thalidomide in renal cell carcinoma. Proc Amer Soc Clin Onc 20:180a, (abstr 718), 2001","journal-title":"Proc Amer Soc Clin Onc"},{"key":"5098311_CR14","first-page":"180a","volume":"20","author":"Z Li","year":"2001","unstructured":"Li Z, Amato R, Papandreou C, Pagliaro L, Kim J, Millikan R, Loggins-Coffman J, Perez C, Logothesis C, Dalani D: Phase II Study of Thalidomide for patients with metastatic renal cell carcinoma (MRCC) progressing after interleukin-2 (IL-2)-based therapy (Rx). Proc Amer Soc Clin Onc 20:180a, (abstr 717), 2001","journal-title":"Proc Amer Soc Clin Onc"},{"key":"5098311_CR15","first-page":"265a","volume":"20","author":"Y Novik","year":"2001","unstructured":"Novik Y, Dutcher JP, Larkin M, Wiernik P: Phase II study of Thalidomide(T) in advanced refractory metastatic renal cell cancer (MRCC): a single institution experience. Proc Amer Soc Clin Onc 20:265a, (abstr 1057), 2001","journal-title":"Proc Amer Soc Clin Onc"},{"key":"5098311_CR16","first-page":"265a","volume":"20","author":"J Vuky","year":"2001","unstructured":"Vuky J, Berg W, Yu R, Ginsberg M, Mazumdar M, Bacik J, Motzer R: Phase II trial of Thalidomide in patients with metastatic renal cell carcinoma. Proc Amer Soc Clin Onc 20:265a, (abstr 1056), 2001","journal-title":"Proc Amer Soc Clin Onc"},{"key":"5098311_CR17","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1054\/bjoc.2001.2025","volume":"85","author":"J Stebbing","year":"2001","unstructured":"Stebbing J, Benson C, Eisen T, Pyle L, Smalley K, Bridle H, Mak I, Sapunar F, Ahern R, Gore ME: The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 85:953\u2013958, 2001","journal-title":"Br J Cancer"},{"key":"5098311_CR18","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood.V98.5.1614","volume":"98","author":"M Zangari","year":"2001","unstructured":"Zangari M, Anissie E, Barlogie B, Badros A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L, Tricot G: Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood 98:1614\u20131615, 2001","journal-title":"Blood"},{"key":"5098311_CR19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/0003-4819-136-9-200205070-00024","volume":"136","author":"B Escudier","year":"2002","unstructured":"Escudier B, Lassau N, Leborgne S, Angevin E, Laplanche A: Thalidomide and venous thrombosis. Ann Int Med 136:711\u2013712, 2002","journal-title":"Ann Int Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020669705369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1023\/A:1020669705369\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1023\/A:1020669705369.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T20:01:41Z","timestamp":1753819301000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1023\/A:1020669705369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["5098311"],"URL":"https:\/\/doi.org\/10.1023\/a:1020669705369","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}